Researchers uncovered a mechanism by which RNA‑guided modulation of STAT3 influences CD4+ T helper cell fate in non‑small cell lung cancer, reshaping epigenetic and epitranscriptomic programs. The study links STAT3‑driven transcriptional control to T‑cell differentiation states that affect tumor immunity and may inform strategies to sensitize tumors to checkpoint inhibitors. STAT3 is a central transcription factor in inflammatory signaling; the paper details how RNA‑guided perturbations shift CD4+ phenotypes within the tumor microenvironment. The findings offer molecular targets for groups developing combination immunotherapies and T‑cell reprogramming approaches.